173 related articles for article (PubMed ID: 34859337)
1. Population Pharmacokinetics of Melphalan in a Large Cohort of Autologous and Allogeneic Hematopoietic Cell Transplantation Recipients: Towards Individualized Dosing Regimens.
Shah GL; Boelens JJ; Carlow D; Lin A; Schofield R; Cruz Sitner N; Alperovich A; Ruiz J; Proli A; Dahi P; Tamari R; Giralt SA; Scordo M; Admiraal R
Clin Pharmacokinet; 2022 Apr; 61(4):553-563. PubMed ID: 34859337
[TBL] [Abstract][Full Text] [Related]
2. Population Pharmacokinetics of Melphalan for Pediatric Patients Undergoing Hematopoietic Cell Transplantation.
Li S; Dvorak CC; Lu Y; Chan D; Gobburu JVS; Long-Boyle J; Apsel Winger B
J Clin Pharmacol; 2022 Jul; 62(7):873-882. PubMed ID: 35048362
[TBL] [Abstract][Full Text] [Related]
3. The pharmacokinetics and pharmacodynamics of busulfan when combined with melphalan as conditioning in adult autologous stem cell transplant recipients.
Willcox A; Wong E; Nath C; Janson B; Harrison SJ; Hoyt R; Bajel A; Shaw P; Ritchie D; Grigg A
Ann Hematol; 2018 Dec; 97(12):2509-2518. PubMed ID: 30051172
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation.
Mizuno K; Dong M; Fukuda T; Chandra S; Mehta PA; McConnell S; Anaissie EJ; Vinks AA
Clin Pharmacokinet; 2018 May; 57(5):625-636. PubMed ID: 28918602
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation.
Dahi PB; Lin A; Scordo M; Flynn JR; Devlin SM; Ruiz JD; DeRespiris L; Carlow D; Cho C; Lahoud OB; Perales MA; Sauter CS; Boelens JJ; Admiraal R; Giralt SA; Shah GL
Transplant Cell Ther; 2022 Aug; 28(8):485.e1-485.e6. PubMed ID: 35545213
[TBL] [Abstract][Full Text] [Related]
6. Effect of the dose per body weight of conditioning chemotherapy on severity of mucositis and risk of relapse after autologous haematopoietic stem cell transplantation in relapsed diffuse large B cell lymphoma.
Costa LJ; Micallef IN; Inwards DJ; Johnston PB; Porrata LF; Litzow MR; Ansell SM
Br J Haematol; 2008 Oct; 143(2):268-73. PubMed ID: 18699848
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the performance of a prior tacrolimus population pharmacokinetic kidney transplant model among adult allogeneic hematopoietic stem cell transplant patients.
Zhu J; Campagne O; Torrice CD; Flynn G; Miller JA; Patel T; Suzuki O; Ptachcinski JR; Armistead PM; Wiltshire T; Mager DE; Weiner DL; Crona DJ
Clin Transl Sci; 2021 May; 14(3):908-918. PubMed ID: 33502111
[TBL] [Abstract][Full Text] [Related]
8. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
[TBL] [Abstract][Full Text] [Related]
9. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
10. Toxicity assessment of concurrent gabapentin/pregabalin administration with high-dose melphalan in autologous hematopoietic cell transplant recipients.
Angus J; Cumpston A; Veltri L; Ross KG; Wen S; Dillaman M
Support Care Cancer; 2021 Dec; 29(12):7925-7930. PubMed ID: 34191128
[TBL] [Abstract][Full Text] [Related]
11. Effect of obesity on outcomes after autologous hematopoietic stem cell transplantation for multiple myeloma.
Vogl DT; Wang T; Pérez WS; Stadtmauer EA; Heitjan DF; Lazarus HM; Kyle RA; Kamble R; Weisdorf D; Roy V; Gibson J; Ballen K; Holmberg L; Bashey A; McCarthy PL; Freytes C; Maharaj D; Maiolino A; Vesole D; Hari P
Biol Blood Marrow Transplant; 2011 Dec; 17(12):1765-74. PubMed ID: 21624486
[TBL] [Abstract][Full Text] [Related]
12. Utilization of a Population Pharmacokinetic Model to Improve a Busulfan Test-Dose Strategy in Allogeneic Hematopoietic Cell Transplant Recipients.
Dunlap TC; Weiner DL; Kemper RM; Kardouh M; DeVane SC; Symonds A; Shaw JR; Armistead PM; Ptachcinski JR; Crona DJ
J Clin Pharmacol; 2023 Sep; 63(9):1026-1035. PubMed ID: 37122163
[TBL] [Abstract][Full Text] [Related]
13. Impact of Dose-Adjusted Melphalan in Obese Patients Undergoing Autologous Stem Cell Transplantation.
Shultes KC; Arp C; Stockerl-Goldstein K; Trinkaus K; DeFrates S
Biol Blood Marrow Transplant; 2018 Apr; 24(4):687-693. PubMed ID: 29225163
[TBL] [Abstract][Full Text] [Related]
14. Test-dose pharmacokinetics guided melphalan dose adjustment in reduced intensity conditioning allogeneic transplant for non-malignant disorders.
Chandra S; Mizuno K; Zhao J; Davies SM; Marsh RA; Fukuda T; Setchell KDR; Vinks AA; Mehta PA
Br J Clin Pharmacol; 2022 Jan; 88(1):115-127. PubMed ID: 34075614
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Dose Adjustment Strategies for Obesity in High-dose Cyclophosphamide Among Adult Hematopoietic Cell Transplantation Recipients: Pharmacokinetic Analysis.
Takahashi T; Jaber MM; Al-Kofahi M; Weisdorf D; Brunstein C; Bachanova V; Brundage RC; Jacobson PA; Kirstein MN
Transplant Cell Ther; 2022 Dec; 28(12):845.e1-845.e8. PubMed ID: 36167308
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of melphalan in paediatric blood or marrow transplant recipients.
Nath CE; Shaw PJ; Montgomery K; Earl JW
Br J Clin Pharmacol; 2007 Aug; 64(2):151-64. PubMed ID: 17324241
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic Hematopoietic Cell Transplantation for Juvenile Myelomonocytic Leukemia with a Busulfan, Fludarabine, and Melphalan Regimen: JPLSG JMML-11.
Sakashita K; Yoshida N; Muramatsu H; Ohtsuka Y; Watanabe K; Yabe M; Kakuda H; Honda Y; Watanabe T; Haba M; Ohmori S; Matsuda K; Yuza Y; Saito A; Horibe K; Adachi S; Manabe A
Transplant Cell Ther; 2024 Jan; 30(1):105.e1-105.e10. PubMed ID: 37806448
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacokinetics of ciclosporin in allogeneic hematopoietic stem cell transplant recipients: C-reactive protein as a novel covariate for clearance.
Ling J; Yang XP; Dong LL; Jiang Y; Zou SL; Hu N; Chen R
J Clin Pharm Ther; 2022 Apr; 47(4):483-492. PubMed ID: 34779003
[TBL] [Abstract][Full Text] [Related]
19. Body weight-dependent pharmacokinetics of busulfan in paediatric haematopoietic stem cell transplantation patients: towards individualized dosing.
Bartelink IH; Boelens JJ; Bredius RG; Egberts AC; Wang C; Bierings MB; Shaw PJ; Nath CE; Hempel G; Zwaveling J; Danhof M; Knibbe CA
Clin Pharmacokinet; 2012 May; 51(5):331-45. PubMed ID: 22455797
[TBL] [Abstract][Full Text] [Related]
20. Clinical Impact of Melphalan Pharmacokinetics on Transplantation Outcomes in Children Undergoing Hematopoietic Stem Cell Transplantation.
Maemura R; Wakamatsu M; Matsumoto K; Sakaguchi H; Yoshida N; Hama A; Yoshida T; Miwata S; Kitazawa H; Narita K; Kataoka S; Ichikawa D; Hamada M; Taniguchi R; Suzuki K; Kawashima N; Nishikawa E; Narita A; Okuno Y; Nishio N; Kato K; Kojima S; Morita K; Muramatsu H; Takahashi Y
Cell Transplant; 2022; 31():9636897221143364. PubMed ID: 36537564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
